8-K: Coeptis Therapeutics Announces 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing

Coeptis Therapeutics will implement a 1-for-20 reverse stock split effective December 30, 2024, to meet Nasdaq's minimum bid price requirement.

Summary

• Coeptis Therapeutics Holdings, Inc. has announced a 1-for-20 reverse stock split of its common stock.
• The reverse stock split was authorized by the Board of Directors and majority shareholders.
• The split will be effective after market close on December 30, 2024, and will begin trading on a post-split basis on December 31, 2024.
• The primary reason for the reverse stock split is to maintain the company's listing on the Nasdaq Capital Market, which requires a minimum bid price of $1.00 per share.
• The reverse split will not change any stockholder's percentage ownership, except for minor adjustments due to the treatment of fractional shares.
• No fractional shares will be issued; instead, any fractional shares will be rounded up to the next whole share.
• The company's transfer agent, Continental Stock Transfer, will act as the exchange agent and will provide instructions to stockholders who hold physical stock certificates.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the need for a reverse stock split to maintain Nasdaq listing, which suggests underlying financial or market perception issues. However, the company is taking proactive steps to address the issue.

Positives

• The reverse stock split is a proactive measure to maintain the company's listing on the Nasdaq Capital Market.
• The company will round up fractional shares to the next whole share, benefiting shareholders who would have otherwise received a fractional share.

Negatives

• The reverse stock split is a result of the company's share price falling below the Nasdaq minimum bid price requirement, which may indicate underlying issues with the company's performance or market perception.

Risks

• The company's inability to maintain the listing of its securities on the Nasdaq Capital Market is a risk factor.
• There are risks associated with the company's products in development failing clinical trials or not being approved by regulatory authorities.
• The company faces risks related to competition, economic factors, and the impact of the global COVID-19 pandemic.

Future Outlook

The company intends to maintain its listing on the Nasdaq Capital Market through the reverse stock split. The company will continue to develop its cell therapy platforms for cancer, autoimmune, and infectious diseases.

Management Comments

• The Board of Directors authorized the reverse stock split.
• The reverse stock split is intended to help the Company meet the minimum bid price requirement necessary to maintain its listing on the Nasdaq Capital Market.

Industry Context

Reverse stock splits are not uncommon in the biopharmaceutical industry, particularly for companies that are struggling to maintain their share price above the minimum listing requirements of exchanges like Nasdaq. This action is often a sign of financial challenges or a need to improve market perception.

Comparison to Industry Standards

• Many small-cap biopharmaceutical companies have had to implement reverse stock splits to maintain their Nasdaq listing.
• Companies like Agenus Inc. and Cellectar Biosciences have also recently undergone reverse stock splits to meet minimum bid price requirements.
• The 1-for-20 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-100.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their percentage ownership will remain the same, except for minor adjustments due to the treatment of fractional shares.
• The reverse stock split is intended to maintain the company's listing on the Nasdaq Capital Market, which is important for investor confidence.

Next Steps

• The reverse stock split will be effective after market close on December 30, 2024.
• Trading on a post-split basis will begin on the Nasdaq Capital Market on December 31, 2024.
• Continental Stock Transfer will send instructions to stockholders of record who hold stock certificates regarding the exchange of their old certificates for new certificates.

Key Dates

Keywords

reverse stock split, Nasdaq Capital Market, minimum bid price, stock listing, biopharmaceutical, cell therapy, COEP, shareholders